🇺🇸 FDA
Patent

US 12171760

Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors

granted A61KA61K2039/505A61K31/444

Quick answer

US patent 12171760 (Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors) held by Corcept Therapeutics Incorporated expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2039/505, A61K31/444, A61K31/4745, A61K31/57